{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field d0059e5d-f533-4292-8ffc-bf628b759333 --><h2>Changes</h2><!-- end field d0059e5d-f533-4292-8ffc-bf628b759333 -->","summary":null,"htmlStringContent":"<!-- begin item 52eb3df3-b602-462f-9420-2dde16344877 --><!-- begin field bcbd3f3b-81fa-459e-afc2-9118c1fa13cd --><p><strong>September 2020 </strong>— minor update. Ticagrelor added as a drug interaction with simvastatin in line with the updated Summary of Product Characteristics.</p><p><strong>August 2020</strong> — minor update. Broken URL links updated and adverse effects of simvastatin updated in line with manufacturer's revised SPC.</p><p><strong>February 2019</strong> — reviewed. A literature search was conducted in February 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. Based on an update of the National Institute for Health and Care (NICE) guideline <em>Familial hypercholesterolaemia: identification and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>], the following key changes have been made to this CKS topic:</p><ul><li>Information on when to suspect familial hypercholesterolaemia (FH) has been amended.</li><li>Information on how to identify people with FH has been added.</li><li>The Dutch Lipid Clinic Network (DLCN) criteria has been included as an alternative to the Simon Broome criteria for making a clinical diagnosis of FH in primary care.</li><li>Advice on the use of coronary heart disease (CHD) risk estimation tools has been amended: CHD risk estimation tools, such as QRISK and those based on the Framingham algorithm, should not be used because people with FH are already at a high risk of premature CHD.</li></ul><!-- end field bcbd3f3b-81fa-459e-afc2-9118c1fa13cd --><!-- end item 52eb3df3-b602-462f-9420-2dde16344877 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6aa48558-01b6-510d-88cf-a4e9e96c1561","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ba2648a1-2e6b-4b77-9cb2-ae52107f24c5 --><h3>Previous changes</h3><!-- end field ba2648a1-2e6b-4b77-9cb2-ae52107f24c5 -->","summary":null,"htmlStringContent":"<!-- begin item 91c15fe1-1013-4069-8f17-28bdcc42d5a2 --><!-- begin field 91cad82e-1157-4e19-8870-b2fb30ce749c --><p><strong>December 2016</strong> —<strong> </strong>minor update. The indications for ezetimibe have been updated in line with the manufacturer's 2016 Summary of Product Characteristics. </p><p><strong>October 2015 </strong>— minor update. Immune-mediated necrotizing myopathy (IMNM) has been included as a very rare adverse effect of some statins. </p><p><strong>July 2015 </strong>— minor updates:</p><ul><li>Following an update to the Summary of Product Characteristics (SPC) for rosuvastatin (Crestor<sup>®</sup>), information on the interaction of rosuvastatin with simeprevir has been added to the Prescribing information section [ABPI, 2015].  </li><li>Minor text change to remove the percentage equivalents of HbA1c mmol/mol values, which are no longer commonly used to diagnose diabetes mellitus.</li></ul><p><strong>May 2015 </strong>— minor updates:</p><ul><li>Following a 2015 update to the SPC for colesevelam, information on the potential drug interaction of colesevelam with olmesartan, metformin, glimepiride, and glipizide has been added to the topic. The adverse effects section has also been updated to include intestinal obstruction as a possible adverse effect of colesevelam.</li><li>Following a 2015 update to the SPC for atorvastatin, as advised by the European Medicines Agency, immune-mediated necrotizing myopathy has been added as a possible adverse effect during or after treatment with atorvastatin (and other statins).  </li></ul><p><strong>February 2015 </strong>—<strong> </strong>reviewed. A literature search was conducted in January 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made; however, new sections have been added to the topic, including prescribing information sections for lipid-modifying drugs and a section on tests that should be implemented before starting lipid-modification treatment.</p><p><strong>November 2012 </strong>—<strong> </strong>minor update. The links to the electronic medicines website (<a data-hyperlink-id=\"32dca9f1-4a3b-466e-890a-a99201385cf0\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) have been updated.</p><p><strong>December 2010 </strong>—<strong> </strong>minor update. Following the publication of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial, the Supporting evidence section has been updated. Issued in December 2010.</p><p><strong>June 2010 </strong>—<strong> </strong>minor update. Following a review of the data from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial, the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks. Issued in June 2010.</p><p><strong>October 2009 </strong>—<strong> </strong>minor update. A reminder from the MHRA that aspirin is not licensed for use in primary prevention of vascular events has been added. Issued in October 2009.</p><p><strong>November 2008 to March 2009 </strong>—<strong> </strong>this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 91cad82e-1157-4e19-8870-b2fb30ce749c --><!-- end item 91c15fe1-1013-4069-8f17-28bdcc42d5a2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}